These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16627255)

  • 21. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of RT-PCR monitoring on the long-term survival in acute promyelocytic leukemia.
    Hu J; Yu T; Zhao W; Gu B; Shen Z; Li X; Sun G; Chen S; Wang Z
    Chin Med J (Engl); 2000 Oct; 113(10):899-902. PubMed ID: 11775836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term therapeutic outcome of patients with acute promyelocytic leukemia].
    Zhang L; Li R; Li DP; Liu YZ; Xu SC; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):15-8. PubMed ID: 17649719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment concepts of acute promyelocytic leukemia.
    Lengfelder E; Saussele S; Weisser A; Büchner T; Hehlmann R
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):261-74. PubMed ID: 16236522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
    Grimwade D; Jovanovic JV; Hills RK; Nugent EA; Patel Y; Flora R; Diverio D; Jones K; Aslett H; Batson E; Rennie K; Angell R; Clark RE; Solomon E; Lo-Coco F; Wheatley K; Burnett AK
    J Clin Oncol; 2009 Aug; 27(22):3650-8. PubMed ID: 19506161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
    Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
    Adès L; Chevret S; Raffoux E; de Botton S; Guerci A; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Maloisel F; Deconinck E; Ferrant A; Thomas X; Fegueux N; Chomienne C; Dombret H; Degos L; Fenaux P;
    J Clin Oncol; 2006 Dec; 24(36):5703-10. PubMed ID: 17116939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
    Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
    Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?
    Mallo M; Salido M; Espinet B; Cervera J; Canellas A; Pajuelo JC; Pedro C; Florensa L; Sanz MA; Solé F
    Leuk Res; 2007 Sep; 31(9):1315-7. PubMed ID: 17092559
    [No Abstract]   [Full Text] [Related]  

  • 31. Acute promyelocytic leukemia: a case-based review.
    Gupta V; Tabak D; Keating A
    Hematology; 2003 Apr; 8(2):105-13. PubMed ID: 12745660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
    Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
    Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA).
    Klein SK; Biemond BJ; van Oers MH
    Ann Hematol; 2007 Dec; 86(12):917-8. PubMed ID: 17619879
    [No Abstract]   [Full Text] [Related]  

  • 35. Reinduction of relapsed acute promyelocytic leukemia with ATRA and low dose antimetabolite-based chemotherapy.
    Dvorak CC; Sanders RP; Dahl GV; Donaldson SS; Razzouk BI
    Pediatr Blood Cancer; 2007 May; 48(5):582-5. PubMed ID: 16123994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The expanding role of arsenic in acute promyelocytic leukemia.
    Tallman MS
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S25-9. PubMed ID: 18760708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia.
    Snijder S; Mellink CH; van der Lelie H
    Cancer Genet Cytogenet; 2008 Jan; 180(2):149-52. PubMed ID: 18206542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemia.
    Castagnola C; Elena C; Merli M
    Haematologica; 2008 Feb; 93(2):e28. PubMed ID: 18245644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.